Czechia· CZ-0255588
PADCEV
A enfortumab vedotin product containing enfortumab vedotin, registered in Czechia by Astellas Pharma Europe B.V., Leiden. The same ATC class is registered in 13 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Enfortumab vedotin is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FX13 (enfortumab vedotin), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 8 of them publish a price we can compare per daily dose
Enfortumab vedotin · ATC L01FX13
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- ENFORTUMAB VEDOTIN
- Manufacturer
- Astellas Pharma Europe B.V., Leiden
- Country
- Czechia (CZ)
- ATC code
- L01FX13
- ATC class
- Enfortumab vedotin
- Defined daily dose
- 9.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl02555881CZK 17232.36
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
190 interactions on record for enfortumab vedotin.
Graded by severity as the source publishes them — 37 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Enfortumab vedotin · interactions on record
190 records
- 37 severe
- 150 moderate
- 3 minor
Most severe, free to view
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
- Darunavir and cobicistatJ05AR14severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Enfortumab vedotin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandPadcevOrifarm Oy
- SpainPADCEV 20 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONAstellas Pharma Europe B.V.
- United KingdomPadcev 20mg powder for concentrate for solution for infusion vialsAstellas Pharma Ltd
- IrelandPadcev 20 mg Powder for concentrate for solution for infusionAstellas Pharma Europe B.V.
- IcelandPadcevAstellas Pharma Europe B.V.
- NorwayPadcevAstellas Pharma Europe B.V. - Leiden
- PolandPadcevAstellas Pharma Europe B.V.
- BelgiumPadcev 20 mgAstellas Pharma Europe
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Padcev
- Liechtenstein · Padcev
- Norway · Padcev
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8dedbc20-d3ff-47d1-8281-675614f9ca8b GET /v1/drugs/8dedbc20-d3ff-47d1-8281-675614f9ca8b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INF PLV CSL",
"source": "sukl",
"strength": "20MG",
"pack_size": "1",
"substance": "ENFORTUMAB VEDOTIN",
"cz_kod_sukl": "0255588",
"product_type": "BT",
"substance_codes": "20188",
"registration_state": "R",
"registration_number": "EU/1/21/1615/001"
}See everything about enfortumab vedotin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.